ArticleEuropean journal of nuclear medicine and molecular imaging2026
Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07168616 (Prospective Evaluation of Istanbul PSMA PET/CT Criteria for Selecting Candidates for Active Surveillance in Low-Risk Prostate Cancer), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Evaluation of Istanbul PSMA PET/CT Criteria for Selecting Candidates for Active Surveillance in Low-Risk Prostate Cancer
Who cites it
2 citing papers in PubMed.
- Is early imaging a pitfall? Effect of [⁶⁸Ga]Ga-PSMA PET/CT timing after biopsy on SUVmax and adverse pathology prediction in low-to-intermediate risk prostate cancer.Annals of nuclear medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop and validate the Istanbul [
methods[
resultsPathological upgrading occurred in 40% of all cases (74% GG1, 20% GG2). Among 56 GG1 patients, upgrading was 76%. SUVmax and PSA were significantly higher in IPPC-3 than in IPPC-2 (SUVmax 16.3 vs. 6.5, p < 0.001; PSA 7.8 vs. 5.3 ng/mL, p < 0.05). ROC analysis yielded an AUC = 0.76 with an optimal SUVmax cut-off of 8.21 (sensitivity 55%, specificity 90%). All lesions with SUVmax ≥ 12.0 corresponded to csPCa. Interobserver agreement was substantial (κ ≈ 0.70-0.74) and intraobserver concordance strong (κ ≈ 0.80-0.90), confirming high reproducibility.
conclusionIPPC provides a reproducible, biologically grounded method that integrates SUVmax, morphology, and anatomical localization to non-invasively refine AS eligibility. By identifying patients at genuine risk for csPCa while minimizing unnecessary biopsies, IPPC may improve confidence and adherence in AS management. Prospective multicentre validation within the ongoing I-SELECT trial (NCT07168616) will determine its broader clinical applicability.
Indexed as
Identifiers
41364230What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.